BioWorld Asia

July 9, 2008

European Biotech Industry Sets Out Tough Agenda

BRUSSELS, Belgium - The European biotech industry is facing a long list of unmet priority tasks, according to its just-released 2008 annual report. (BioWorld International) Read More

Shire Paying Jerini $519M for HAE Compound Firazyr

SkyPharma's Flutiform Meets Endpoint in 3rd Phase III Trial

Study Boosts Serotonin Theory for Crib Death

Cellectis, Regeneron Settle Licensing Disagreement

ExonHit Attacking Alzheimer's in Therapeutic, Diagnostics

MediGene's RhuDex on Hold After Death of Trial Volunteer

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...

GT-02897 exerts efficacy in preclinical multiple myeloma

BioWorld Science

Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...